The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer
Open accessAbstract
BACKGROUND: Oropharyngeal squamous-cell carcinomas caused by human papillomavirus (HPV) are associated with favorable survival, but the independent prognostic significance of tumor HPV status remains unknown. METHODS: We performed a retrospective analysis of the association between tumor HPV status and survival among patients with stage III or IV oropharyngeal squamous-cell carcinoma who were enrolled in a randomized trial comparing accelerated-fractionation radiotherapy (with acceleration by means of concomitant boost radiotherapy) with standard-fractionation radiotherapy, each combined with cisplatin therapy, in patients with squamous-cell carcinoma of the head and neck. Proportional-hazards models were used to compare the risk of death among patients with HPV-positive cancer and those with HPV-negative cancer. RESULTS: The median follow-up period was 4.8 years. The 3-year rate of overall survival was similar in the group receiving accelerated-fractionation radiotherapy and the group receiving standard-fractionation radiotherapy (70.3% vs. 64.3%; P=0.18; hazard ratio for death with accelerated-fractionation radiotherapy, 0.90; 95% confidence interval [CI], 0.72 to 1.13), as were the rates of high-grade acute and late toxic events. A total of 63.8% of patients with oropharyngeal cancer (206 of 323) had HPV-positive tumors; these patients had better 3-year rates of overall survival (82.4%, vs. 57.1% among patients with HPV-negative tumors; P<0.001 by the log-rank test) and, after adjustment for age, race, tumor and nodal stage, tobacco exposure, and treatment assignment, had a 58% reduction in the risk of death (hazard ratio, 0.42; 95% CI, 0.27 to 0.66). The risk of death significantly increased with each additional pack-year of tobacco smoking. Using recursive-partitioning analysis, we classified our patients as having a low, intermediate, or high risk of death on the basis of four factors: HPV status, pack-years of tobacco smoking, tumor stage, and nodal stage. CONCLUSIONS: Tumor HPV status is a strong and independent prognostic factor for survival among patients with oropharyngeal cancer. (ClinicalTrials.gov number, NCT00047008.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multiple Imputation for Nonresponse in Surveys
Rubin, D. B. (1987) · Wiley Series in Probability and Statistics · doi:10.1002/9780470316696 · Cited by 20,701
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982) · AMERICAN JOURNAL OF CLINICAL ONCOLOGY · doi:10.1097/00000421-198212000-00014 · Cited by 11,647
Cox, J. D., Stetz, J., & Pajak, T. F. (1995) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(95)00060-c · Cited by 4,792
Evidence for a Causal Association Between Human Papillomavirus and a Subset of Head and Neck Cancers
Gillison, M. L. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.9.709 · Cited by 3,101
Self-citationPignon, J.-P., Maître, A. L., Maillard, E., & Bourhis, J. (2009) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2009.04.014 · Cited by 3,069
Fakhry, C., Westra, W. H., Li, S., Cmelak, A., Ridge, J. A., Pinto, H., Forastiere, A., & Gillison, M. L. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn011 · Cited by 2,779
Self-citationHuman Papillomavirus Types in Head and Neck Squamous Cell Carcinomas Worldwide: A Systematic Review
Kreimer, A. R., Clifford, G. M., Boyle, P., & Franceschi, S. (2005) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-04-0551 · Cited by 2,184
Adelstein, D. J., Li, Y., Adams, G. L., Wagner, H., Kish, J. A., Ensley, J. F., Schuller, D. E., & Forastiere, A. A. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.01.008 · Cited by 1,748
Gillison, M. L., D'Souza, G., Westra, W., Sugar, E., Xiao, W., Begum, S., & Viscidi, R. (2008) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djn025 · Cited by 1,543
Self-citationFu, K. K., Pajak, T. F., Trotti, A., Jones, C. U., Spencer, S. A., Phillips, T. L., Garden, A. S., Ridge, J. A., Cooper, J. S., & Ang, K. K. (2000) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(00)00663-5 · Cited by 1,357
Self-citation
Cited by
Items 101–109 of 109
Detection of Solid Tumor Molecular Residual Disease (MRD) Using Circulating Tumor DNA (ctDNA)
Chin, R.-I., Chen, K., Usmani, A., Chua, C., Harris, P. K., Binkley, M. S., Azad, T. D., Dudley, J. C., & Chaudhuri, A. A. (2019) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-019-00390-5 · Cited by 191
Powell, S. F., Gold, K. A., Gitau, M. M., Sumey, C. J., Lohr, M. M., McGraw, S. C., Nowak, R. K., Jensen, A. W., Blanchard, M. J., Fischer, C. D., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03156 · Cited by 116
Karamboulas, C., Bruce, J. P., Hope, A. J., Meens, J., Huang, S. H., Erdmann, N., Hyatt, E., Pereira, K., Goldstein, D. P., Weinreb, I., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.10.004 · Cited by 94
HPV E2, E4, E5 drive alternative carcinogenic pathways in HPV positive cancers
Ren, S., Gaykalova, D. A., Guo, T., Favorov, A. V., Fertig, E. J., Tamayo, P., Callejas-Valera, J. L., Allevato, M., Gilardi, M., Santos, J., et al. (2020) · Oncogene · doi:10.1038/s41388-020-01431-8 · Cited by 93
Morgan, I., DiNardo, L., & Windle, B. (2017) · Viruses · doi:10.3390/v9080208 · Cited by 65
Variable expression of the forgotten oncogene E5 in HPV-positive oropharyngeal cancer
Um, S. H., Mundi, N., Yoo, J., Palma, D. A., Fung, K., MacNeil, D., Wehrli, B., Mymryk, J. S., Barrett, J. W., & Nichols, A. C. (2014) · Journal of Clinical Virology · doi:10.1016/j.jcv.2014.06.019 · Cited by 31
The Use of HPV16-E5, EGFR, and pEGFR as Prognostic Biomarkers for Oropharyngeal Cancer Patients
Taberna, M., Torres, M., Alejo, M., Mena, M., Tous, S., Marquez, S., Pavón, M. A., León, X., García, J., Guix, M., et al. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00589 · Cited by 26
Jelinek, M. J., Foster, N. R., Zoroufy, A. J., Schwartz, G. K., Munster, P. N., Seiwert, T. Y., de Souza, J. A., & Vokes, E. E. (2021) · Oral Oncology · doi:10.1016/j.oraloncology.2020.105171 · Cited by 20
“Although advances have been made in HNSCC, HPV-negative disease consistently demonstrates 3-year survival rates nearly 30% below HPV-positive tumors.[2, 35] Despite the addition of novel agents, such as cetuximab and avelumab, to definitive chemoradiation, outcomes have not improved.”
BackgroundBauml, J., Kim, J., Zhang, X., Aggarwal, C., Cohen, R. B., & Schmitz, K. (2017) · Journal of Cancer Survivorship · doi:10.1007/s11764-017-0604-5 · Cited by 10
Metadata
- Authors
- Ang, K. K., Harris, J., Wheeler, R., Weber, R., Rosenthal, D. I., Nguyen-Tân, P. F., Westra, W. H., Chung, C. H., Jordan, R. C., Lu, C., Kim, H., Axelrod, R., Silverman, C. C., Redmond, K. P., & Gillison, M. L.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-07
- Volume
- 363
- Issue
- 1
- Pages
- 24-35
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2110664940
- Cited by
- 6,566
- References
- 25
- FWCI
- 261.03
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.